- The first patient has been dosed in a P-II study evaluating the safety & preliminary efficacy of onvansertib + Irinotecan and 5-FU in ~40 patients as a 2L treatment for metastatic PDAC who have failed 1L gemcitabine-based therapy across 6 sites in the US
- The 1EPs of the study is ORR and 2EPs include DoR, m-OS, ORR in patients receiving more than two treatment cycles, DCS, and assessment of KRAS allelic burden in liquid biopsies as measured by ctDNA
- The ongoing P-II trial of onvansertib + irinotecan and 5-FU for KRAS-mutated mCRC showed clinical benefit and improve outcomes. Additionally, the company is also expected the similar results in PDAC trial
Click here to read full press release/ article | Ref: PR Newswire | Image: Cardiff Oncology
The post Cardiff Oncology Reports First Patient Dosing in P-II Trial for Onvansertib + Irinotecan and 5-FU as a 2L Treatment for Metastatic Pancreatic Ductal Adenocarcinoma first appeared on PharmaShots.